Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties.
SH-SY5Y neuroblastoma cells and solution metal-binding assays.
Reported findings. No therapeutic benefit measured; zinc complex strength and zinc influx were comparable with parent Semax.
Nonresponse. Acetylated Semax did not protect cells against copper-induced toxicity.
Harms. Human adverse outcomes/safety not assessed.
Limits. Cell assays do not establish cognitive or human therapeutic benefits. Amidates, Adamax and Selank are not this preparation. Original funding/conflict wording inaccessible; indexed funding identified separately.
Preparation: N-terminally acetylated MEHFPGP; C-terminal amidation not reported in accessible abstract. Route: Solution/cultured-cell exposure; no human delivery route.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.